On Dec. 23, Sanofi filed the complaint in the U.S. District Court for the District of New Jersey. The complaint calls for Novo Nordisk to pay an undisclosed amount in money damages and remove marketing materials for its insulin drug Tresiba.
Sanofi alleges the marketing materials encourage physicians and patients to switch from Lantus and Toujeo – Sanofi’s insulin drugs – to Tresiba because the former drugs will be “blocked” by CVS Caremark in January.
However, Sanofi said CVS is replacing its insulin drugs on the pharmacy’s standard list of drugs most insurers cover with a similar, cheaper version made by Indianapolis-based Eli Lilly. Sanofi said many insurers will likely still pay for its insulin drugs, although patients may have to pay more for them.
More articles on legal & regulatory issues:
Cardinal Health reaches $44M settlement with DOJ
5 latest healthcare industry lawsuits, settlements
Minnesota chiropractors accused of insurance fraud
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
